MARKET

NRXP

NRXP

NRX Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.42
-0.59
-5.89%
After Hours: 9.50 +0.08 +0.85% 19:58 09/24 EDT
OPEN
10.04
PREV CLOSE
10.01
HIGH
10.08
LOW
9.33
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
76.99
52 WEEK LOW
8.39
MARKET CAP
506.55M
P/E (TTM)
-1.2396
1D
5D
1M
3M
1Y
5Y
NRX Pharmaceuticals Files Shelf for Up to 2.9 Million Common Shares on Behalf of Selling Securityholders
MT Newswires · 09/16 05:45
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
Zacks.com · 09/14 15:42
NNVC, LIFE and DATS pre market gainers
Communications Systems JCS +27% declares $3.50 special dividend NanoViricides (NYSE:NNVC) +21% completes licensing for Coronavirus field which includes current COVID-19 drug development aTyr Pharma (NASDAQ:LIFE) +13%. DatChat (NASDAQ:DATS) +10%. SeaChange ...
Seekingalpha · 09/14 12:22
Why Are NRx Pharma Shares Moving Higher On Tuesday Premarket?
Benzinga · 09/14 12:17
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.
Benzinga · 09/14 11:13
IQVIA And NRx Pharmaceuticals Collaborate On Potential Medical Support For Novel COVID-19 Treatment
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx
Benzinga · 09/13 20:16
Relief provides regulatory update for RLF-100 in U.K.
Relief Therapeutics (OTCQB:RLFTF) has received scientific advice from U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) relating to its lead investigational drug, RLF-100 (aviptadil), for the treatment of respiratory deficiency
Seekingalpha · 09/13 07:15
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRXP. Analyze the recent business situations of NRX Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About NRXP
NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Webull offers kinds of NRX Pharmaceuticals Inc stock information, including NASDAQ:NRXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRXP stock methods without spending real money on the virtual paper trading platform.